All

How to Afford CPAP + GLP-1 Polytherapy

What can sleep physicians do when obstructive sleep apnea patients can't afford every recommended therapy?

All

Sleep Medicine Demands Narrative, Not Just Better Access

New referral pathways and consumer awareness may bring millions into sleep medicine. But if clinicians ignore physiologic heterogeneity and narrative context, more testing could still produce fragmented care.

All

OSA Doesn’t Take Weekends Off. Sleep Testing Often Does.

The identification of 'social apnea' suggests testing protocols may miss peak disease burden—and misclassify risk.

OpenLoop Expands Into Sleep Diagnostics With Happy Sleep Partnership

Apr 22, 2026 | Home Apnea Testing

The telehealth platform is adding at-home sleep apnea testing via the FDA-cleared Happy Ring to help close the gap in OSA diagnosis and care.

12-Month Results from LivaNova’s OSPREY Clinical Study Published

Apr 21, 2026 | Neurostimulators

Full data set demonstrates proximal hypoglossal nerve stimulation yields clinically significant and sustained improvements for patients with moderate to severe OSA.

Vivos Reports 16% Revenue Increase in 2025 Following Business Model Shift

Apr 21, 2026 | Oral Appliances

The medical device company’s new strategy focuses on acquiring and partnering with sleep specialty medical providers, driving revenue growth and a path toward positive cash flow.

Apnimed Secures Up to $150 Million to Support Planned Commercial Launch of AD109

Apr 7, 2026 | Emerging Compounds, Financial, Obstructive Sleep Apnea

The financing will fund commercial readiness for the investigational oral obstructive sleep apnea therapy ahead of an anticipated new drug application.

Study Links High Night-to-Night Variability in OSA to Accelerated Vascular Aging

Apr 2, 2026 | Mattress-Based Sleep Trackers, Obstructive Sleep Apnea

Real-world data from nearly 30,000 adults suggest single-night assessments may underestimate cardiovascular risks associated with sleep-disordered breathing.

Vivos Therapeutics’ Supported Practices Achieve In-Network Status in Nevada

Mar 31, 2026 | Medicare & Medicaid, Oral Appliances

Physician-owned practices supported by Vivos in Nevada are now in-network with major commercial insurers and Medicare, expanding patient access to its sleep apnea treatments.

FDA Approves Expanded MRI Compatibility for Inspire IV and V

Mar 27, 2026 | Neurostimulators

The expanded clearance allows patients with moderate to severe obstructive sleep apnea using the latest Inspire implants to undergo high-resolution 3.0 Tesla MRI scans under specified conditions.

Philips Meets Requirements to Offer DreamStation BiPAP AVAPS for Lower-Weight Patients

Mar 23, 2026 | CPAP & PAP Devices

The devices are designated as medically necessary for a limited patient population older than 7 years and weighing 40 to 66 lbs who have obstructive sleep apnea and respiratory impairment.

Saline Nasal Spray Shows Efficacy in Treating Pediatric Sleep-Disordered Breathing

Mar 20, 2026 | Over-the-Counter Treatments

A new Australian study finds that a simple saline nasal spray can resolve symptoms of obstructive sleep-disordered breathing in children, potentially reducing the need for surgery and specialist care.

Sunrise HST Tested Against PSG

Mar 19, 2026 | Home Apnea Testing

The trial, which enrolled 849 adults across 18 sleep centers in France, directly compares the two diagnostic pathways in routine clinical practice.

Hospital Increases Sleep Testing Capacity by 290% With Dropship Model

Mar 18, 2026 | Home Apnea Testing

The transition from in-office device pickup to a direct-to-patient model via Wesper eliminated the backlog and enabled multi-night studies and at-home CPAP titration.

Will The CPAP Algorithm Boom Deliver Real Innovation?

Mar 14, 2026 | CPAP & PAP Devices

New positive airway pressure algorithms show increased comfort and reduced side effects. The unanswered question is whether they will meaningfully change long-term adherence.

Incannex Updates Clinical Pathway for Sleep Apnea Drug Candidate IHL-42X

Mar 12, 2026 | Emerging Compounds, Obstructive Sleep Apnea

The biopharmaceutical company will initiate a phase 2 dose-optimization study for its oral OSA therapy before advancing to a streamlined phase 3 program.

Not All AHI Metrics Are Equivalent in RPM OSA Management

Mar 5, 2026 | Remote Monitoring

Longitudinal wearable monitoring suggests clinicians may be over-relying on PAP-derived metrics when assessing treatment success. A sleep center founder recommends a different type of remote patient monitoring solution.

Comorbid Insomnia-Sleep Apnea Linked to Higher Cardiovascular Risk in Veterans

Mar 4, 2026 | Insomnia, Obstructive Sleep Apnea

Research involving nearly 1 million US veterans identifies the combination of insomnia and obstructive sleep apnea as a distinct risk state for hypertension and cardiovascular disease.

Tag: OSA

All

All

All